臺灣博碩士論文加值系統

中 文 摘 要
在工業化國家中，心血管疾病(包括高血壓、動脈粥樣硬化、心肌梗塞和腦中風等)的死亡率極高，使得心血管疾病的成因和影響因素在最近二十年來被大力的研究。1970年代的研究即已發現，葡萄酒攝取與心血管疾病死亡率有顯著負相關的關係存在。 近年來的研究又發現，紅葡萄酒可使大白鼠的血管平滑肌產生舒張作用，紅葡萄酒中的重要成分檞皮酮在血管平滑肌產生舒張作用時扮演著重要角色。因此本實驗在探討檞皮酮對於大白鼠，血管平滑肌的作用機轉。離體實驗部份，將取自正常血壓鼠或L-NAME所誘導之高血壓大白鼠的胸主動脈，連接於張力轉能器，記錄對藥物的收縮或舒張反應。結果顯示，在無內皮細胞存在的狀況下，檞皮酮(10-4 M)能抑制血清胺所引起的血管收縮反應，但檞皮酮(10-4 M)卻不能抑制phenylephrine所引起的血管收縮反應。由本論文的結果顯示，檞皮酮選擇性抑制血清胺收縮反應的機轉，無法被一氧化氮合成酵素抑制劑或前列腺素合成酵素抑制劑所阻斷。所以檞皮酮可能不是經由一氧化氮或是前列腺素來達成抑制血清胺所引發的收縮反應。
慢性腹腔給予檞皮酮(四週)雖無法抑制L-NAME所誘發的高血壓，但可使高血壓鼠的血管對phenylephrine 的收縮性顯著被抑制。檞皮酮由於可抑制血清胺(急性效果)及phenylephrine(慢性效果)的收縮反應，因此檞皮酮在治療心血管疾病的療效上值得進一步去探討。

Abstract
Since the early 1970s, there have been increasing evidences that the consumption of moderate amounts of red wine is inversely correlated with the mortality of myocardial infarction. Quercetin, the major component of the red wine may be involved in the prevention of cardiovascular diseases. In an isolated vessel preparation, aortic rings from Sprague-Dawley rats or L-NAME induced hypertensive rats were placed in tissue baths to record isometric tension. Our results demonstrated that quercetin (10-4 M) selectively inhibits the vascular contraction induced by serotonin (10-10 ~3 X 10-5 M). In contrast, quercetin did not inhibit the vascular contraction induced by phenylephrine. This inhibitory effect of quercetin on serotonin-induced vascular contraction was not prevented by pretreatment the vessels with indomethacin or L-NAME. Our results indicate that nitric oxide and prostaglandin may not involve in the acute effects of quercetin on serotonin-induced vascular contraction. In chronic L-NAME induced hypertensive rats, daily injection of quercetin did not prevent the progress of hypertension. However,chronic quercetin injection inhibited the vascular contraction induced by phenylephrine in L-NAME induced hypertensive rats. In summary, quercetin acutely inhibited serotonin-induced vascular contraction and chronically inhibited phenylephrine-induced vascular contraction suggesting a potential role for further clinical application.

論文目錄
目錄 I
中 文 摘 要 III
英 文 摘 要 V
第一章 緒論 1
1-1 心血管疾病簡介 2
1-2 血清胺與心血管系統的關係 6
1-3 血清胺與心血管疾病的關係 8
1-4 實驗藥物簡介 11
1-5 實驗目的 17
第二章 材料與方法 18
2-1 實驗動物 19
2-2 實驗藥物 20
2-3 實驗方法 21
2-4 數據分析 25
第三章 結果 27
3-1 對正常血壓鼠的離體實驗 28
3-2 慢性飲用L-NAME誘導高血壓 32
3-3 慢性給予quercetin，是否改變 33
高血壓鼠對藥物的反應性
3-4 實驗結果附圖 35
第四章 討論 57
4-1 檞皮酮擴張血管的機轉 58
4-2 評估檞皮酮對於L-NAME所誘發後天性 62
高血壓大白鼠的療效
第五章 結論 64
第六章 參考文獻 66

1. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI: Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol. 1989 Jun 1;38(11):1763-9.
2. Andriambeloson E, Stoclet JC, Andriantsitohaina R: Mechanism of endothelial nitric oxide-dependent vasorelaxation induced by wine polyphenols in rat thoracic aorta.J Cardiovasc Pharmacol. 1999 Feb;33(2):248-54.
3. Apisariyakul A, Chaichana N, Takemura H: Dual effects of quercetin on contraction in cardiac and skeletal muscle preparations. Res Commun Mol Pathol Pharmacol. 1999;105(1-2): 129-38.
4. Auch-Schwelk W: Coronary spasm--a clinically relevant problem ? Herz. 1998 Mar;23(2):106-15.
5. Beil W, Birkholz C, Sewing KF: Effects of flavonoids on parietal cell acid secretion, gastric mucosal prostaglandin production and Helicobacter pylori growth. Arzneimittelforschung. 1995 Jun; 45(6): 697-700.
6. Belougne-Malfatti E. Aguejouf O. Doutremepuich F. Doutremepuich C. Action of neurotransmitters: acetylcholine, serotonin, and adrenaline in an experimental arterial thrombosis induced by oxygen free radicals. Thrombosis Research. 88(5):435-9, 1997 Dec 1. 98215519
7. Bjeldanes LF, Chang GW: Mutagenic activity of quercetin and related compounds. Science. 1977 Aug 5;197(4303):577-8.
8. Bom AH, Villalon CM, Verdouw PD, Saxena PR: The 5-HT1-like receptor mediating reduction of porcine carotid arteriovenous shunting by RU 24969 is not related to either the 5-HT1A or the 5-HT1B subtype. Eur J Pharmacol. 1989 Nov 14;171(1):87-96.
9. Cheav SL, Prigent AF, Picq M, Foussard-Blanpin O, Pacheco H: Cardiovascular action of penta-O-ethylquercetin in the rat. Arch Int Pharmacodyn Ther. 1989 Mar-Apr;298:108-24.
10. Chen CK, Pace-Asciak CR: Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol. 1996 Mar; 27(2):363-6.
11. Cishek MB, Galloway MT, Karim M, German JB, Kappagoda CT: Effect of red wine on endothelium-dependent relaxation in rabbits.
Clin Sci (Colch). 1997 Dec;93(6):507-11.
12. Damas J, Mousty JC, Lecomte J: Changes, induced by certain flavonoids, of the hypotensive effects of arachidonic acid. C R Seances Soc Biol Fil. 1977;171(1):257-60. French.
13. Demrow HS, Slane PR, Folts JD: Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation. 1995 Feb 15;91(4):1182-8.
14. Diaz MN, Frei B, Vita JA, Keaney JFJ: Antioxidants and atherosclerotic heart disease.N Engl J Med. 1997 Aug 7;337(6):408-16.
15. Duarte J, Perez Vizcaino F, Utrilla P, Jimenez J, Tamargo J, Zarzuelo A: Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. Gen Pharmacol. 1993 Jul;24(4): 857-62.
16. Duarte J, Perez-Vizcaino F, Zarzuelo A, Jimenez J, Tamargo J: Inhibitory effects of quercetin and staurosporine on phasic contractions in rat vascular smooth muscle. Eur J Pharmacol. 1994 Sep 1;262(1-2):149-56.
17. Faggiotto A, Ross R, Harker L: Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation.Arteriosclerosis. 1984 Jul-Aug;4(4):323-40.
18. Flesch M, Schwarz A, Bohm M: Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol. 1998 Oct;275(4 Pt 2):H1183-90.
19. Frishman WH, Grewall P: Serotonin and the heart. Ann Med. 2000 Apr;32(3):195-209.
20. Frishman WH: Recent advances in cardiovascular pharmacology. Curr Probl Cardiol. 2000 Apr;25(4):227-95.
21. Hosokawa N, Hosokawa Y, Sakai T, Yoshida M, Marui N, Nishino H, Kawai K, Aoike A: Inhibitory effect of quercetin on the synthesis of a possibly cell-cycle-related 17-kDa protein, in human colon cancer cells. Int J Cancer. 1990 Jun 15;45(6):1119-24.
22. Hu JP, Calomme M, Lasure A, De Bruyne T, Pieters L, Vlietinck A, Vanden Berghe DA: Structure-activity relationship of flavonoids with superoxide scavenging activity. Biol Trace Elem Res. 1995 Jan-Mar;47(1-3):327-31.
23. Huang YT, Lin HC, Chang YY, Yang YY, Lee SD, Hong CY: Hemodynamic effects of synephrine treatment in portal hypertensive rats. Jpn J Pharmacol. 2001 Feb;85(2):183-8.
24. Kim HP, Mani I, Iversen L, Ziboh VA: Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs.Prostaglandins Leukot Essent Fatty Acids. 1998 Jan;58(1):17-24.
25. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H: Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy. 2000 Apr;30(4):501-8.
26. Kitagawa S, Fujisawa H, Kametani F, Sakurai H: Generation of active oxygen species in blood platelets--spin trapping analysis.Free Radic Res Commun. 1992;15(6):319-24.
27. Mirzoeva OK, Calder PC: The effect of propolis and its components on eicosanoid production during the inflammatory response. Prostaglandins Leukot Essent Fatty Acids. 1996 Dec;55(6): 441-9.
28. Morales MA, Lozoya X: Calcium-antagonist effects of quercetin on aortic smooth muscle. Planta Med. 1994 Aug;60(4):313-7.
29. Nair GV, Gurbel PA, O'Connor CM, Gattis WA, Murugesan SR, Serebruany VL: Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am J Cardiol. 1999 Aug 1;84(3):321-3, A8.
30. Ranelletti FO, Maggiano N, Serra FG, Ricci R, Larocca LM, Lanza P, Scambia G, Fattorossi A, Capelli A, Piantelli M: Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer. 2000 Feb 1;85(3):438-45.
31. Revuelta MP, Cantabrana B, Hidalgo A: Depolarization- dependent effect of flavonoids in rat uterine smooth muscle contraction elicited by CaCl2. Gen Pharmacol. 1997 Nov;29(5): 847-57.
32. Robak J, Shridi F, Wolbis M, Krolikowska M: Screening of the influence of flavonoids on lipoxygenase and cyclooxygenase activity, as well as on nonenzymic lipid oxidation. Pol J Pharmacol Pharm. 1988 Sep-Oct;40(5):451-8.
33. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s.Nature. 1993 Apr 29;362(6423):801-9.
34. Stary HC: Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults.Arteriosclerosis. 1989 Jan-Feb;9(1 Suppl):I19-32.
35. Tamargo J: Clinical pharmacology of calcium antagonists. Rev Esp Cardiol. 1994 Dec;47(12):824-35.
36. Van Nueten JM, Janssens WJ, Vanhoutte PM: Serotonin and vascular reactivity. Pharmacol Res Commun. 1985 Jul;17(7):585-608.
37. Wu YJ, Leng XF: Comparison of effects of verapamil and quercetin on delayed polyneuropathy induced by Tri-o-cresyl phosphate in hens. Bull Environ Contam Toxicol. 1997 Apr;58(4):611-8.
38. Yuasa S, Li X, Hitomi H, Hashimoto M, Fujioka H, Kiyomoto H, Uchida K, Shoji T, Takahashi N, Miki S, Miyatake A, Mizushige K, Matsuo H: Sodium sensitivity and sympathetic nervous system in hypertension induced by long-term nitric oxide blockade in rats. Clin Exp Pharmacol Physiol. 2000 Jan-Feb;27(1-2):18-24.
39. Zhukova AV, Sagach VF: Role of eicosanoids in the postischemic shock development. Pol J Pharmacol. 1996 Jan-Feb;48(1):23-9.